Plegridy

SOMETHING DIFFERENT IS TAKING SHAPE IN INTERFERON THERAPY

PLEGRIDY (peginterferon beta-la) is the only pegylated interferon beta for the treatment of relapsing multiple sclerosis.

Indication
PLEGRIDY (peginterferon beta-la) is indicated for the treatment of patients with relapsing forms of multiple sclerosis.

SIGNIFICANT REDUCTIONS IN CLINICAL AND MRI ENDPOINTS

EVERY-TWO-WEEKS PLEGRIDY FOR ONLY 26 SUBCUTANEOUS INJECTIONS PER YEAR

Dose titration at treatment initiation is recommended

Instruct patients on the proper technique for self-administering subcutaneous injections

Advise patients to rotate the areas of injection with each dose to minimize the likelihood of injection site reactions

Prophylactic and concurrent use of analgesics and/or antipyretics may prevent or ameliorate flu-like symptoms sometimes experienced during treatment with PLEGRIDY

Biogen

plegridy
(peginterferon beta-la)

---

Download this ad as separate pages in JPEG format.
Brand: Plegridy
Country/Market: USA, North America
Target: Healthcare Professional (HCP)
Size/duration: Two-page ad
Publication/Aired:
Neurology - April 15, 2015

---

See more Plegridy ads here